Patents
Methods for identifying stem cells based on nuclear morphotypes
Patent Number: 7,427,502Stem cells are usually identified based on markers such as CD34 for hematopoietic stem cells, or CD133 for cancer stem cells, or specific properties such as expression of aldehyde dehydrogenase. Interestingly, in this patent the morphological characteristics of the stem cell are covered !The first...
Inventors: Gostjeva; Elena V. (Winchester, MA), Thilly; William G. (Winchester, MA)
Assignee: Massachusetts Institute of Technology (Cambridge, MA)
Date of First Priority Issue: Thursday June 17th, 2004
Method of treating brain tissue damages
Patent Number: 7,427,597It is known that various endogenous repair processes exist after ischemic injury to the brain. For example, in stroke patients, there is a correlation between improvement of neurological function and amount of circulating stem cells. Attempts are being made to augment endogenous repair processes by administration of agents such as
Assignee: Academia Sinica (Taipei, TW)
Date of First Priority Issue: Monday November 21st, 2005
Method of enhancing proliferation and/or hematopoietic differentiation of stem cells
Patent Number: 7,427,603The use of hematopoietic stem cells for numerous conditions has been around for decades, originally of course in the form of allogeneic bone marrow transplant, and more recently various variations such as autologous transplantation, autologous transplantation and purging, and autologous transplantation for non-hematopoietic conditions such as cardiac infarction. One of the limiting factors...
Inventors: Zon; Leonard I. (Wellesley, MA), Davidson; Alan J. (West Roxbury, MA), Daley; George Q. (Weston, MA)
Assignee: The Children's Medical Center Corporation (Boston, MA)
Date of First Priority Issue: Thursday September 26th, 2002
Modulation of C-reactive protein expression
Patent Number: 7,425,545Inflammatory mediators are known to attract stem cells in acute settings, and inhibit stem cells in chronic settings. For example, in stroke patients, there is an increase in SDF-1, which is believed to account for mobilization of stem cells from the bone marrow into systemic circulation, and from there, presumably into the brain, where they mediate trophic and...
Inventors: Crooke; Rosanne M. (Carlsbad, CA), Graham; Mark J. (San Clemente, CA)
Assignee: Isis Pharmaceuticals, Inc. (Carlsbad, CA)
Date of First Priority Issue: Monday June 2nd, 2003
Cardiomyocyte precursors from human embryonic stem cells
Patent Number: 7,425,448Geron has taken a very strategic approach to embryonic stem cells. They inlicensed composition of matter patents on embryonic stem cells, such as #5,843,780 from the Wisconsin Alumni Research Foundation (WARF), they patented methods of culturing embryonic stem cells in serum free conditions so to allow for clinical use (#
Assignee: Geron Corporation (Menlo Park, CA)
Date of First Priority Issue: Thursday July 12th, 2001
Somatic pluripotent cells
Patent Number: 7,422,736Numerous patents exist on various types of stem cells. For example, Osiris has overarching patents on any cell that expresses the mesenchymal stem cell markers SH2, SH3, or SH4. An example of which is US patent # 5,486,359, in which the broadest claim covers "An isolated, homogeneous population of human mesenchymal stem cells which can differentiate...
Inventors: Hwang; Shiaw-Min (Hsinchu, TW)
Assignee: Food Industry Research and Development Institute (TW)
Date of First Priority Issue: Wednesday June 26th, 2002
Compounds to promote regeneration of bone marrow
Patent Number: 7,423,029This patent covers the use of heterocyclic trialkyl ammonium-containing compounds for stimulation of bone marrow proliferation and differentiation after myeloablation or other insults to the hematopoietic stem cell compartment. The toxicity profile of the compounds appears favorable.Data in the examples section demonstrates protection from cyclophosphamide destruction of the bone...
Inventors: Kiss; Zoltan (Austin, MN)
Assignee: Zoltan Laboratories, LLC (Austin, MN)
Date of First Priority Issue: Friday March 23rd, 2007
Method for enhancing proliferation of bone marrow cells or spleen cells with an ethanol-insoluble extract of dioscorea
Patent Number: 7,419,690There has been a great interest in patenting natural compounds and plant derivatives for manipulation of the stem cell compartment. For example, there is an issued patent covering seaweed extract for mobilization of stem cells, pine cone extracts for dendritic cell differentiation, and now the use of Yam extracts for...
Inventors: Yang; Ning-Sun (Taipei, TW), Su; Pei-Fen (Keelong, TW), Li; Chin-Jin (Taipei, TW), Shyur; Lie-Fen (Taipei, TW)
Assignee: Academia Sinica (Taipei, TW)
Date of First Priority Issue: Monday December 1st, 2003
Isolation of neural stem cells using gangliosides and other surface markers
Patent Number: 7,419,825This patent covers a method of isolating neural stem cells by the surface marker CD15. This protein is found on neutrophils and other immune cells, known more for its adhesion functions and sugar-binding activity. Previously another patent (US # 7,182,946) touched upon the utility of this marker for purification of neural stem cells.The patent does...
Inventors: Klassen; Henry (Pasadena, CA), Schwartz; Michael (Garden Grove, CA), Young; Michael J. (Gloucester, MA)
Assignee: Children's Hospital of Orange County (Orange, CA)
Date of First Priority Issue: Friday April 20th, 2001
Methods for use of MPL ligands with primitive human stem cells
Patent Number: 7,416,887Thrombopoietin, otherwise known as the mpl ligand, is a potent stimulator of platelet production. Several companies are working on clinically implimenting this agent for patients with chemotherapy associated thrombocytopenia. For example, Ligand Pharmaceuticals has a patent on a thrombopoietic mimetic.The current patent teaches how to used...
Inventors: Murray; Lesley J (San Jose, CA), Young; Judy C (San Carlos, CA)
Assignee: Novartis AG (Cambridge, MA)
Date of First Priority Issue: Monday October 30th, 1995